Anti cdkn1b

Western blots were performed using anti-DNMT3A (Abcam, Cambridge, UK) and mouse anti-cyclinD1, anti-CDK4, anti-CDK6, anti-p18^INK4C, and anti-CDKN1B which were purchased as part of a Cell Cycle Regulation Sampler Kit (Cell Signaling Technology). Mouse anti-β-actin was obtained from Sigma-Aldrich. Protein detection was performed with Super Signal Chemiluminescence Substrate (Pierce, USA).

A549 and H1299 (adenocarcinomic human alveolar basal epithelial cell line which is a NSCLC cell line) were obtained from NCCS (National Center for Cell Science). The cells were grown in high glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (Gibco, Thermo Fischer Scientific). Anti PPARG (CST#2435), anti-BAX (CST#2772), anti-BCL2 (CST#2872) and anti-CASP3 (CST#9665), anti CDKN1A (CST#2947), phospho AKT (CST#9271), AKT (CST#9272), anti-CDKN1B (CST#3698), anti TP53 (CST#48818), ACTB (CST#4970), phospho P44/42 (CST#9101), and P44/42 (CST#4695) antibodies were purchased from cell signaling technologies. PARP1 (MA5-15031) was purchased from pierce. Anti rabbit FITC (#65-6111) was procured from Thermo Fischer Scientific. GAPDH (sc-25778) was obtained from Santa Cruz. Gamma H2AX antibody (MABE205) was purchased from Merck. Rosiglitazone (CAS number-122320-73-4), PI (CAS number-25535-16-4) and Annexin V-PI kit (APOAF-50TST), crystal violet (C0775) were procured from Sigma.

Western blot analysis was performed as previously described (Lan et al., 2019 (link)). The antibodies used were anti-phosphoAMPK (Thr172), anti-AMPK, anti−phosphoAkt (Ser473), anti-panAkt, anti-CDKN1B (Cell Signaling Technology, Danvers, MA, United States), anti-cyclin D1 (Abcam, Cambridge, MA, United States), and anti-β-actin (Novus Biologicals, Littleton, CO, United States) antibodies.